Skip to main navigation
Skip to search
Skip to main content
University of Copenhagen Research Portal Home
Help & FAQ
Dansk
English
Home
Profiles
Research output
Research units
Press/Media
Activities
Prizes
???studenttheses???
Datasets
Search by expertise, name or affiliation
Investigational drugs in clinical trials for Hidradenitis Suppurativa
Peter Theut Riis
*
, Linnea R. Thorlacius,
Gregor B. Jemec
*
Corresponding author for this work
Department of Clinical Medicine
25
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Investigational drugs in clinical trials for Hidradenitis Suppurativa'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Investigational Drugs
100%
Clinical Trials
100%
Hidradenitis Suppurativa
100%
Phase I Trial
50%
Hidradenitis
50%
Phase II Trial
50%
New Drugs
25%
Meta-analysis
25%
Botulinum Toxin B
25%
Expert Opinion
25%
Unmet Medical Need
25%
Clinical Response
25%
Phosphodiesterase 4 Inhibitor
25%
Triamcinolone Acetonide
25%
New Treatment Options
25%
Interleukin-17 (IL-17)
25%
EudraCT
25%
Benzoyl Peroxide
25%
Clinical Trial Registry
25%
Area Cover
25%
Treatment Options
25%
Interleukin-1β
25%
Adalimumab
25%
Targets for Therapy
25%
Chronic Skin Disease
25%
Randomized Controlled Trial
25%
Metformin
25%
Medicine and Dentistry
Clinical Trial
100%
Hidradenitis Suppurativa
100%
Investigational Drug
100%
Phase II Trials
50%
Hidradenitis
50%
Phase I Trials
50%
Meta-Analysis
25%
Adalimumab
25%
Interleukin 1
25%
Phosphodiesterase IV Inhibitor
25%
Randomized Controlled Trial
25%
Interleukin 17
25%
Dermatosis
25%
Glycon
25%
Immunosuppressant
25%
Triamcinolone
25%
Pharmacology, Toxicology and Pharmaceutical Science
Suppurative Hidradenitis
100%
Clinical Trial
100%
Investigational Drug
100%
Phase I Trials
50%
Phase II Trials
50%
Randomized Controlled Trial
25%
Interleukin 1
25%
Immunosuppressive Agent
25%
Botulinum Toxin B
25%
Triamcinolone
25%
Secukinumab
25%
Skin Disease
25%
Phosphodiesterase IV Inhibitor
25%
Metformin
25%
Interleukin 17
25%
Adalimumab
25%
Benzoyl Peroxide
25%